Absolute Risk and Attributable Fraction of Type-Specific Human Papillomavirus in Cervical Cancer and Precancerous Lesions—A Population-Based Study of 6286 Women in Rural Areas of China

Background: To investigate the human papillomavirus (HPV) genotype distribution among the general population and assess the attribution of HPV genotypes targeted by vaccines to protect against cervical lesions theoretically. Methods: Cervical samples were collected from women aged 21 to 64 years old from Inner Mongolia and Shanxi Province in China who had not been vaccinated against HPV. HPV type-specific absolute risk (AR) to classified cervical lesions was calculated and then the attributable fraction (AF) was estimated, together with the combined contributions of the HPV types, targeted by four available HPV vaccines and five HPV vaccines in clinical trials in China to protect against cervical lesions. Results: A total of 6286 women with an average age of 44.1 years ± 8.41 (range: 21–64) participated in the study. The age distribution of 14 HR-HPV and HPV16/18 all showed a ‘U’ shape, which peaked in the ≤25 year-group and >55 year-group. The five most common genotypes were HPV16 (4.3%), HPV52 (4.1%), HPV58 (2.1%), HPV51 (2.1%), and HPV66 (1.7%). The prevalence of HPV types 6 and 11 infections was 1.1% and observed with n significant differences across age stratifications in China. AF to CIN2+ was predominated by HPV 16 with 56.2%, followed by HPV58 (12.0%), HPV52 (8.5%), HPV18 (4.3%), and HPV51 (2.9%). HPV52 and 58 in the prophylactic HPV vaccine would enhance the protection against CIN2+ by approximately 20%. Conclusions: Regarding multi-valent HPV vaccine development in China, the HPV types 16, 52, 58, and 18 should be given priority for their high prevalence at the population level, high AR, notable AF, and high relative risk to high-grade cervical lesions.

[1]  N. Matsumura,et al.  Human papillomavirus genotype contribution to cervical cancer and precancer: Implications for screening and vaccination in Japan , 2020, Cancer science.

[2]  H. Zou,et al.  Cervical human papillomavirus among women in Guangdong, China 2008‐2017: Implication for screening and vaccination , 2019, Journal of medical virology.

[3]  Y. Qiao,et al.  Projections up to 2100 and a budget optimisation strategy towards cervical cancer elimination in China: a modelling study. , 2019, The Lancet. Public health.

[4]  Hong Yu,et al.  The prevalence and genotype distribution of human papillomaviruses among women in Taizhou, China , 2019, Medicine.

[5]  Yunshan Wang,et al.  Patients With LR-HPV Infection Have a Distinct Vaginal Microbiota in Comparison With Healthy Controls , 2019, Front. Cell. Infect. Microbiol..

[6]  Kai Wang,et al.  HPV genotype prevalence and distribution during 2009–2018 in Xinjiang, China: baseline surveys prior to mass HPV vaccination , 2019, BMC Women's Health.

[7]  Y. Qiao,et al.  Efficacy of quadrivalent human papillomavirus vaccine against persistent infection and genital disease in Chinese women: A randomized, placebo-controlled trial with 78-month follow-up. , 2019, Vaccine.

[8]  R. Shao,et al.  Screening for HPV infection in exfoliated cervical cells of women from different ethnic groups in Yili, Xinjiang, China , 2019, Scientific Reports.

[9]  R. Zheng,et al.  [Report of cancer epidemiology in China, 2015]. , 2019, Zhonghua zhong liu za zhi [Chinese journal of oncology].

[10]  Yanqing Ding,et al.  Prevalence and distribution of human papillomavirus genotypes among women with high‐grade squamous intraepithelial lesion and invasive cervical cancer in Ganzhou, China , 2018, Journal of clinical laboratory analysis.

[11]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[12]  L. Sui,et al.  Distribution of human papilloma virus genotype prevalence in invasive cervical carcinomas and precancerous lesions in the Yangtze River Delta area, China , 2018, BMC Cancer.

[13]  Xia Li,et al.  Trends of incidence rate and age at diagnosis for cervical cancer in China, from 2000 to 2014. , 2017, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[14]  Suyoung Kim,et al.  Human Papillomavirus Genotype Distribution Among 18,815 Women in 13 Korean Cities and Relationship With Cervical Cytology Findings , 2017, Annals of laboratory medicine.

[15]  Y. Ke,et al.  Whole-Genome Analysis of Human Papillomavirus Types 16, 18, and 58 Isolated from Cervical Precancer and Cancer Samples in Chinese Women , 2017, Scientific Reports.

[16]  F. Zhao,et al.  High-risk human papillomavirus genotype distribution and attribution to cervical cancer and precancerous lesions in a rural Chinese population , 2017, Journal of gynecologic oncology.

[17]  E. Pirog,et al.  The variable clinicopathological categories and role of human papillomavirus in cervical adenocarcinoma: A hospital based nation‐wide multi‐center retrospective study across China , 2016, International journal of cancer.

[18]  L. Villa,et al.  HPV genotype distribution in Brazilian women with and without cervical lesions: correlation to cytological data , 2016, Virology Journal.

[19]  Y. Qiao,et al.  Risk assessment to guide cervical screening strategies in a large Chinese population , 2016, International journal of cancer.

[20]  M. Schiffman,et al.  Triage of HPV positive women in cervical cancer screening. , 2016, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[21]  Y. Gu,et al.  Genotype distribution characteristics of high-risk human papillomaviruses in women from Shanghai, China , 2015, Epidemiology and Infection.

[22]  T. Weiss,et al.  Global availability of data on HPV genotype-distribution in cervical, vulvar and vaginal disease and genotype-specific prevalence and incidence of HPV infection in females , 2015, Infectious Agents and Cancer.

[23]  A. Del Mistro,et al.  Age and geographic variability of human papillomavirus high-risk genotype distribution in a large unvaccinated population and of vaccination impact on HPV prevalence. , 2014, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[24]  Y. Qiao,et al.  Comparison of HPV genotypes and viral load between different sites of genital tract: the significance for cervical cancer screening. , 2014, Cancer epidemiology.

[25]  Clare Gilham,et al.  Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials , 2014, The Lancet.

[26]  Karen Canfell,et al.  The burden of cervical cancer in China: Synthesis of the evidence , 2012, International journal of cancer.

[27]  Beibei Lu,et al.  Efficacy and Safety of Prophylactic Vaccines against Cervical HPV Infection and Diseases among Women: A Systematic Review & Meta-Analysis , 2011, BMC infectious diseases.

[28]  N. Muñoz,et al.  Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. , 2010, The Lancet. Oncology.

[29]  Martyn Plummer,et al.  Concurrent Infection with Multiple Human Papillomavirus Types: Pooled Analysis of the IARC HPV Prevalence Surveys , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[30]  M. Madeleine,et al.  A Systematic Review of the Prevalence and Attribution of Human Papillomavirus Types among Cervical, Vaginal, and Vulvar Precancers and Cancers in the United States , 2008, Cancer Epidemiology Biomarkers & Prevention.

[31]  W. Quint,et al.  Comparison of the SPF10-LiPA System to the Hybrid Capture 2 Assay for Detection of Carcinogenic Human Papillomavirus Genotypes among 5,683 Young Women in Guanacaste, Costa Rica , 2007, Journal of Clinical Microbiology.

[32]  C. Meijer,et al.  Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination. , 2005, The Journal of infectious diseases.

[33]  Xavier Castellsagué,et al.  Against which human papillomavirus types shall we vaccinate and screen? the international perspective , 2004, International journal of cancer.

[34]  Y. Qiao,et al.  Shanxi Province cervical cancer screening study II: Self‐sampling for high‐risk human papillomavirus compared to direct sampling for human papillomavirus and liquid based cervical cytology , 2003, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[35]  A. Moscicki,et al.  External genital warts: diagnosis, treatment, and prevention. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  Mark Sherman,et al.  The 2001 Bethesda System: terminology for reporting results of cervical cytology. , 2002, JAMA.

[37]  C J L M Meijer,et al.  The causal relation between human papillomavirus and cervical cancer. , 2002, Journal of clinical pathology.

[38]  R. Newcombe.  Two-sided confidence intervals for the single proportion: comparison of seven methods. , 1998, Statistics in medicine.

[39]  C. Wheeler,et al.  Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts , 1995, Journal of clinical microbiology.

[40]  G. Keating,et al.  Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a guide to its use in the EU , 2014, Drugs & Therapy Perspectives.

[41]  Du Hon.  Current situation of cervical HPV infection in females in Gansu Province , 2015 .

[42]  Bo Huang,et al.  Genotype distribution of human papillomavirus in women with abnormal cervical cytology in an esophageal carcinoma high incidence area of China. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[43]  J. Cuzick,et al.  Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. , 2012, The Lancet. Oncology.

[44]  L. Gissmann,et al.  Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers. , 1983, Proceedings of the National Academy of Sciences of the United States of America.